Phentermine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Phentermine: From Appetite Suppression to Hypervitaminosis
One-Sentence Summary
Phentermine is a sympathomimetic amine typically used as an appetite suppressant, though no confirmed original indication is documented in this evidence pack. The TxGNN model predicts a possible link to Hypervitaminosis, but currently 0 clinical trials and 0 publications support this direction — the prediction is model-output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (no original_indications or license data provided) |
| Predicted New Indication | Hypervitaminosis |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for phentermine (marked as a data gap). Based on the model’s own rationale text, phentermine is understood as a sympathomimetic amine that promotes central norepinephrine release, historically associated with appetite suppression — but this has not been confirmed against a documented original indication in this evidence pack.
For the top-ranked prediction, hypervitaminosis, there is no known metabolic or toxicological mechanism connecting phentermine’s central nervous system stimulant activity to vitamin-overdose pathology. The evidence pack’s own repurposing rationale explicitly flags this: the high TxGNN score likely reflects node proximity in the knowledge graph rather than a true biological mechanism. The same caveat applies to the other ranked candidates (16p11.2 microdeletion syndrome, hypertelorism, frontorhiny) — all are structural/genetic disorders with no plausible pharmacological link to a sympathomimetic amine, and several involve obsolete or rare ontology terms that are more likely graph noise than genuine signal.
In short, this is a pure model-prediction case (L5) with no mechanistic, clinical, or literature support. None of the four ranked candidates should be treated as biologically credible without independent validation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug interaction data are not available in this evidence pack.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5), with zero clinical trials or literature evidence, and the model’s own rationale suggests the top candidate association is likely an artifact of knowledge-graph proximity rather than genuine biology. The drug is also not currently marketed (0 licenses), and core safety data (MOA, TFDA warnings/contraindications) are missing — this is a Blocking data gap that prevents any S1 safety evaluation.
To proceed, the following is needed:
- Confirmed original indication and regulatory license data for phentermine
- Mechanism of action (MOA) data (currently a High-severity data gap)
- TFDA label warnings/contraindications (currently a Blocking-severity data gap)
- Independent mechanistic or preclinical evidence linking phentermine to hypervitaminosis before considering escalation beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.